Moderna is testing a new COVID-19 vaccine in an early-stage study

75756A5E-120A-4932-810C-2FD980DB785E
By , KNX 1070 NEWSRADIO

A patient has been dosed with a new Moderna vaccine candidate in an early-stage study.

The new COVID-19 vaccine candidate can be potentially placed and shipped in refrigerators, according to reporting from Reuters, which wrote that the new candidate, mRNA-1283, is being evaluated as a potential booster shot.

"The early-stage study will assess the safety and immunogenicity of the next-generation vaccine, designated as mRNA-1283, at three dose levels, and will be given to healthy adults either as a single dose or in two doses 28 days apart," the company said in the Reuters story.

The new vaccine candidate could be good for developing countries.

At the moment, the United States is using Pfizer and Moderna vaccines - both of which are two doses - and the newly approved Johnson & Johnson which is one dose.

In the past, Moderna’s CEO Stephane Bancel spoke out about the potential immunity offered by the COVID-19 vaccine.

LISTEN NOW on the RADIO.COM App
Follow RADIO.COM
Facebook | Twitter | Instagram

Featured Image Photo Credit: Nurse manager Lucy Golding draws up doses of the Moderna COVID-19 vaccine before health workers administered the shots to immigrants and undocumented residents ages 55 and over on March 14, 2021 in Stamford, Connecticut. The non-profit Building One Community organized the event to administer the first dose of the Moderna vaccine to more than 350 people from the immigrant community. The vaccines were supplied by the federal Health Resources and Services Administration (HRSA), and injected by Community Health Center workers. Vaccine recipients are due to return in April for their second dose. (Photo by John Moore/Getty Images)